961 / 1266
Summary
•
Dabrafenib was well tolerated in pediatric
patients
•
Phase 2 recommended doses were identified and
different in children ≤12 years and children >12
years based on PK parameters
•
Radiographic responses (44%) and prolonged
stable disease (19%) were seen across a number
of tumor types driven by BRAFV600 mutations
•
The multistrata phase 2 component of trial is
open and accruing around the world
115